Omega Grade supplies analytical-grade research peptides, each lot independently tested and publicly documented. No claims. No dosing guidance. Just traceable, third-party-verified material dispatched from Europe and Asia.
Featured · Retatrutide · 40 mg penTriple-receptor agonist — pre-filled research pen, 4 × 10 mg.
Retatrutide (LY-3437943) is an investigational once-weekly triple agonist at the GLP-1, GIP, and glucagon receptors, currently in Phase 3 (TRIUMPH programme) under Eli Lilly. The 39-amino-acid peptide carries a C20 fatty-diacid moiety that extends plasma half-life via albumin binding.
04:22:11▸lot 26-04-A received ┈ 5.00 g04:22:40▸weight check ┈ PASS ±0.4 mg04:23:12▸sample → janoshik ┈ 50 mg04:23:12▸tracking #jnk-921833405:18:03▸HPLC result ┈ 99.24 %05:18:04▸MS obs 4729.42 Da ┈ PASS05:18:05▸coa.pdf signed ┈ attached05:18:06▸lot approved ┈ LIVE
Every entry is stocked in our UK warehouse with a current analytical certificate on file. Same-day dispatch by 09:30. Click into any record for the full specification, published studies, and lot-specific COA.
Triple-receptor agonist — pre-filled research pen, 4 × 10 mg.
Triple-receptor agonist — 30 mg vial, full research kit.
Triple-receptor agonist — 10 mg vial, full research kit.
Long-acting amylin analogue — GLP-1 stack partner.
Paired regenerative peptides — combined kit, most-requested blend.
Synthetic thymosin β-4 — 43-residue actin-sequestering peptide.
Pentadecapeptide — 15-residue fragment of a gastric body-protection protein.
Oral / sublingual tablet presentation — 60 tablets × 500 mcg.
High-dose pen format — 20 mg BPC-157 + 20 mg TB-500.
Copper-bound tripeptide Gly-His-Lys.
Pre-filled copper-tripeptide pen — high-dose presentation.
Multi-peptide dermal blend — GHK-Cu + supporting peptides.
Pre-filled dermal-blend pen — 140 mg presentation.
Melanocortin-receptor agonist — cyclic heptapeptide.
Linear α-MSH analogue — MC1R-selective melanocortin agonist.
Approved MC3R/MC4R agonist — cyclic heptapeptide.
Cosmetic octapeptide — argireline extension analogue.
Selective growth-hormone secretagogue — pentapeptide.
Long-acting GHRH analogue with Drug Affinity Complex.
Short-acting GHRH (1-29) analogue — no DAC linker.
Approved GHRH analogue — stabilised long-acting GRF(1-44).
GHRH(1-29) analogue — the minimum fragment with full GH-releasing activity.
Non-selective ghrelin-receptor agonist — hexapeptide.
Modified IGF-1 — reduced IGFBP binding, ~83-residue analogue.
Mitochondrial-derived 16-residue peptide — high-dose kit.
NAD⁺ coenzyme — 500 mg kit presentation.
High-dose NAD⁺ pen — 1000 mg pre-reconstituted.
NNMT inhibitor — small-molecule metabolic research tool.
hGH C-terminal fragment — lipolytic research peptide.
Pan-ERR agonist — small-molecule metabolic research tool.
ACTH-derived heptapeptide — Russian nootropic research peptide.
Semax in nasal-spray formulation — intranasal delivery research.
Tuftsin-derived heptapeptide — Russian anxiolytic research peptide.
Selank in nasal-spray formulation.
Nonapeptide isolated from cerebral venous blood.
Phenothiazine dye — research-grade 30% aqueous solution.
Proprietary multi-peptide formulation.
Additional consumables — 20 insulin syringes, swabs.
10 mL bacteriostatic water for injection — 0.9% benzyl alcohol.
3 mL bacteriostatic water for injection.
Looking for a peptide not on the list? Custom dispatch accepted on 2–4 week lead time, subject to analytical approval.
Open correspondenceEvery lot is sampled, dispatched to Janoshik Analytical in Slovakia, and verified by reverse-phase HPLC and electrospray mass spectrometry. Certificates publish before the lot lists for sale.
REPORT ID JA-26-04-012
SUBJECT Retatrutide
DESIGNATION LY-3437943
LOT 26-04-A
METHOD RP-HPLC, ESI-MS
COLUMN C18, 250 x 4.6 mm, 5 um
MOBILE PHASE A: 0.1% TFA in H2O
B: 0.1% TFA in ACN
GRADIENT 5 -> 65% B over 20 min
FLOW RATE 1.0 mL/min
DETECTION UV 214 nm
INJECTION 20 uL @ 0.5 mg/mL
---
PURITY (A%) 99.24
MASS EXP. 4729.40 Da
MASS OBS. 4729.42 Da
---
CONCLUSION Identity CONFIRMED · Purity PASS
SIGNED BY J. Novak, MSc · Janoshik Analytical SVK
DATE 2026-04-11We link directly to the peer-reviewed literature for every peptide in the catalogue — NEJM, The Lancet, Cell Metabolism, Nature Communications. Clinical-trial status is stated honestly: preclinical where preclinical, Phase 3 where Phase 3, approved where approved.
A short version lives here. The complete FAQ covers shipping, payment, returns, and product-specific questions.
Full FAQ